ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
Operating Income
ABVC Biopharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Operating Income
-$8.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-70%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Operating Income
-$282.2m
|
CAGR 3-Years
30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-12%
|
|
Karuna Therapeutics Inc
NASDAQ:KRTX
|
Operating Income
-$494.8m
|
CAGR 3-Years
-90%
|
CAGR 5-Years
-103%
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Operating Income
-$4.2B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
Operating Income
-$94.8m
|
CAGR 3-Years
46%
|
CAGR 5-Years
25%
|
CAGR 10-Years
0%
|
See Also
What is ABVC Biopharma Inc's Operating Income?
Operating Income
-8.2m
USD
Based on the financial report for Dec 31, 2023, ABVC Biopharma Inc's Operating Income amounts to -8.2m USD.
What is ABVC Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-70%
Over the last year, the Operating Income growth was 46%. The average annual Operating Income growth rates for ABVC Biopharma Inc have been 1% over the past three years , -24% over the past five years , and -70% over the past ten years .